Literature DB >> 14998510

New dawn for phage therapy.

Bernard Dixon.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 14998510     DOI： 10.1016/S1473-3099(04)00951-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  5 in total

1.  Experimental phage therapy against Staphylococcus aureus in mice.

Authors:  Rosanna Capparelli; Marianna Parlato; Giorgia Borriello; Paola Salvatore; Domenico Iannelli
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 2.  Phages and their potential to modulate the microbiome and immunity.

Authors:  Sara Federici; Samuel P Nobs; Eran Elinav
Journal:  Cell Mol Immunol       Date:  2020-09-08       Impact factor: 11.530

3.  The role of regulated clinical trials in the development of bacteriophage therapeutics.

Authors:  Helena Mrt Parracho; Ben H Burrowes; Mark C Enright; Malcolm L McConville; David R Harper
Journal:  J Mol Genet Med       Date:  2012-04-23

4.  Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker--case report.

Authors:  P Leszczyński; B Weber-Dabrowska; M Kohutnicka; M Luczak; A Górecki; A Górski
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629

5.  Complete Genome Sequence of the Pseudomonas fluorescens Bacteriophage UFV-P2.

Authors:  Monique R Eller; Rafael L Salgado; Pedro M P Vidigal; Maura P Alves; Roberto S Dias; Leandro L de Oliveira; Cynthia C da Silva; Antônio F de Carvalho; Sérgio O De Paula
Journal:  Genome Announc       Date:  2013-01-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.